FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.
What happened
FDA inspected Chemspec's drug manufacturing facility in Navi Mumbai, India, from July 28 to August 1, 2025. Investigators found that the company made and released API lots without batch manufacturing records, distributed lots without documented quality unit review and release, discarded original executed records, and let production staff document past steps after the fact. FDA said the response of August 21, 2025, was inadequate and noted similar deviations were cited in an untitled letter dated February 5, 2025.
What FDA found
The quality unit released API lots without creating or keeping batch production records, and only investigated after FDA investigators cited it.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); ICH Q7Multiple API lots were distributed without any documented quality unit review and release.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); ICH Q7Two separate logbooks for issuing lot numbers produced two batch records for the same lot number, and two batch records in production had no control number or issuance record.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); ICH Q7Original CGMP records, including many pages of executed batch records and a lab testing record, were discarded and replaced with blank forms without a documented investigation.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Production staff who had not performed or witnessed earlier operations wrote weights, solvent amounts and temperatures into API batch records after the fact instead of at the time of the step.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)FDA had cited similar CGMP deviations in an untitled letter dated February 5, 2025, showing that management oversight and control are inadequate.
What FDA wants
FDA tells Chemspec to reply in writing within 15 working days with a full remediation plan for the quality unit, a corrective and preventive action plan for documentation, a data integrity investigation with root causes, a risk assessment for patients, and a management strategy. FDA strongly recommends hiring a qualified consultant to help.
Who should pay attention
- US finished-dose manufacturers that buy APIs or intermediates from this site
- brands and distributors sourcing APIs from Indian suppliers
- quality and supply chain teams qualifying API suppliers
This is a summary. Read the original letter on fda.gov.